Increasing efficiency and throughput in downstream separation and purification performance is currently a major focus in the biopharmaceutical industry. Traditional TFF systems cannot be scaled in a linear fashion to meet the projected demand for fermentation and cell culture based products. NCSRT has created a patented line of filtration solutions that address the bottlenecks currently experienced as biopharmaceutical products scale up from clinical trials to blockbuster production quantities.
Increasing efficiency and throughput in downstream separation and purification performance is currently a major focus in the biopharmaceutical industry. Traditional TFF systems cannot be scaled in a linear fashion to meet the projected demand for fermentation and cell culture based products. NCSRT has created a patented line of filtration solutions that address the bottlenecks currently experienced as biopharmaceutical products scale up from clinical trials to blockbuster production quantities.
SmartFlow TFF: NCSRT's novel SmartFlow technology incorporates a patented ribbed design that forces uniform flow across the entire membrane surface unlike traditional TFF cassettes. The incorporation of these unique ribs is the result of applying this practical design approach to TFF fuid dynamics. The improved fluid dynamics extends the performance well beyond what is possible with traditional TFF.
OPTISEP SmartFlow Module Performance: NCSRT customer application data shows significant improvements in cell harvesting applications as compared to other TFF formats and combinations of centrifuges and dead end filtration. Independent tests demonstrate the higher flux and increased throughput of the OPTISEP modules in E. Coli harvest (Figure 1).1
Figure 1
For cell harvesting or clarification applications, target protein recoveries consistently achieve >99% recovery in optimized SmartFlow TFF systems. Chubet et al. report a scale up strategy to achieve over 99% target protein recovery using a novel single module filtration process to harvest, concentrate, and diafilter SARS-CoV spike protein from insect cell culture at the 1,000- liter scale.2 Kopf and Kacmar demonstrate the effect of membrane polymer chemistry at high shear (12,000 sec-1) on protein recovery from CHO cell culture (Figure 2).3
Figure 2
The performance advantage provided by OPTISEP SmartFlow TFF also applies to protein concentration applications.
OPTISEP filter modules accommodate ultra, micro, and nano filtration, and reverse osmosis membranes, enabling optimal processing solutions in the laboratory, pilot plant, and manufacturing suite. The modules are available in the variety of pore size, polymer, and supports. The OPTISEP product family provides direct linear scale up without loss of efficiency from 1 ft.2 (0.09 m2 ) to full systems operating over 8560 ft.2 (800 m2 ).
1. Davies ET, Tellez M, and Unger M. Isolation of proteins from fermentation broth of high cell density with a new cross flow filtration. Aachen Membrane Colloquium Proceedings. Aachen, Germany; 2005 Apr.
2. Chubet R, Kacmar J, and Kopf H. Development of a novel platform FF system for insect cell culture harvest. Advances in Separations and Purification Supplement to Biopharm Int. 2006; Jun 3.
3. Kopf H and Kacmar J. The effects of membrane pore size, material composition and volumetric challenge on flux performance and protein passage from CHO cell culture. Antibody Development and Production. Carlsbad, CA; March 1-3.
Company info
NCSRT, Inc.
1000 Goodworth Dr.
Apex
NC 27539
Tel: 919.387.8460
Email: mvanderhoff@ncsrt.com
Website: www.ncsrt.com
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Personalized CRISPR Therapy Successfully Treats Infant With Rare, Incurable CPS1 Deficiency
May 16th 2025A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.
Top 10 Cleanroom Problems That Can Be Prevented via Preventative Maintenance (May 2025)
May 16th 2025Cleanrooms require strict environmental control to maintain sterility, prevent contamination, and ensure seamless operations. Without a proactive preventative maintenance (PM) program, various issues can arise, leading to costly downtime, contamination risks, and operational inefficiencies. Below are ten common cleanroom problems that can be effectively mitigated through proper PM practices.